I

Immunic
D

IMUX

1.07000
USD
0.05
(4.39%)
Market Open
Volume
10,269
EPS
-1
Div Yield
-
P/E
-1
Market Cap
96,384,547
OverviewSignalsIdeasNews
Related Instruments
    I
    IMAB
    0.01060
    (1.12%)
    0.96020 USD
    I
    IMAX
    -0.210
    (-0.86%)
    24.300 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    I
    IMVT
    -0.025
    (-0.10%)
    25.875 USD
    I
    INSM
    -0.340
    (-0.48%)
    70.100 USD
    I
    IONS
    0.220
    (0.62%)
    35.850 USD
    More
News

Title: Immunic

Sector: Healthcare
Industry: Biotechnology
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.